Quarterly report [Sections 13 or 15(d)]

Net Earnings (Loss) Per Share

v3.26.1
Net Earnings (Loss) Per Share
3 Months Ended
Mar. 31, 2026
Earnings Per Share [Abstract]  
Net Earnings (Loss) Per Share

Note 11 - Net Earnings (Loss) Per Share

 

Basic earnings (loss) per share excludes dilution and is computed by dividing income available to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted earnings (loss) per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or otherwise result in the issuance of common stock that shared in the earnings of the entity. Diluted earnings (loss) per share also utilizes the treasury stock method which prescribes a theoretical buy back of shares from the theoretical proceeds of all options outstanding during the period, and the if-converted method for convertible debt.

 

The following is a reconciliation of the weighted average number of common shares outstanding used in calculating basic and diluted net loss per share (in thousands):

 

    March 31, 2026     March 31, 2025  
    For the three months ended  
    March 31, 2026     March 31, 2025  
Loss from continuing operations after income taxes   $ (5,354 )    $ (4,678 )
Income from discontinued operations, net of tax     -       8,644  
Net (loss) income   $ (5,354 )   $ 3,966  
Weighted average common shares outstanding:                
Basic     12,317       3,523  
Diluted     12,317       3,523  
Net earnings (loss) per share:                
Loss from continuing operations, basic and diluted   $ (0.43 )    $ (1.33 )
Income from discontinued operations, basic and diluted   $ -     $ 2.45  
Net loss (earnings) per share, basic and diluted   $ (0.43 )    $ 1.13  

 

 

ProPhase Labs, Inc. and Subsidiaries

Notes to Condensed Consolidated Financial Statements

(unaudited)

 

The following table represents the number of securities excluded from the income per share computation as a result of their anti-dilutive effect (in thousands):

 

Anti-dilutive securities   March 31, 2026     March 31, 2025  
    For the three months ended  
Anti-dilutive securities   March 31, 2026     March 31, 2025  
Common stock purchase warrants     997       74  
Stock options     478       472  
Convertible notes     10,981       -  
Anti-dilutive securities     12,456       546